BlossomHill Therapeutics

BLSM · United States

Share price · BLSM

$14.59-1.51 (-9.38%) 3M

close as of 2026-11-18 · 24h delayed · vol 280K (1.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BLSM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+13.2%
  2. 26 Oct 2026+12.0%

Share of unusual movement by asset

For each asset, the share of BLSM's own-move activity since 10 Aug 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
BH-30643
events and moves
5shown from 8 days
BH-30236
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—20%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—64%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1/2
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1
CLK (CDC-like kinase family)Small molecule
Acute Myeloid Leukemia

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
2026-09-30 Financial ReportEarnings report
Expected report date 2026-12-18 · Fiscal period ending 2026-09-30
What to watch
2029 (1)
January 2029 (1)
BH-30643Phase 1/2NSCLC (Advanced Non-small Cell Lung Cancer)
Est. primary completion 2029-01-31 · NCT06706076 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$22M$225M$24M-$22M operating cash flowreport ↗
View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$21M$95M$24Mreport ↗
2025-Q3—$15M$68M$16M-$12M operating cash flowreport ↗
2025-Q2—$13M$79M$13Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$137M—report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$100M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 7 purchases ($25.2M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-10ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC · director; directorConversion1,039,996——Form 4
2026-08-10GORDON CARL L · directorConversion1,039,996——Form 4
2026-08-10ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC · director; directorConversion1,049,283——Form 4
2026-08-10GORDON CARL L · directorConversion1,049,283——Form 4
2026-08-10ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC · director; directorOpen-market purchase625,000$16.00$10.0MForm 4
2026-08-10GORDON CARL L · directorOpen-market purchase625,000$16.00$10.0MForm 4
2026-08-10ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC · director; directorConversion (derivative)1,039,996——Form 4
2026-08-10GORDON CARL L · directorConversion (derivative)1,039,996——Form 4